Pfizer remains an attractive income stock, yielding 6.22% and trading at 9.3 times the 2026 expected earnings per share. Its non-COVID business is growing operationally by 5%, supported by a strong pipeline and $1.5 billion ahead of its 2026 business targets. Management aims to achieve $9.7 billion in cost savings by 2029, which will help maintain dividend payments despite patent expirations and fund research and development. The author is optimistic about Pfizer's dividend safety and growth prospects beyond 2028, adding to their position for income while awaiting new product catalysts.
Pfizer's market capitalization stands at $157.65 billion with a dividend yield of 6.22% as of September 21, 2026, 22:42 WIB. The stock price on Pluang is USD 27.62, showing a slight increase of 0.07% on the day. This strong yield aligns with the company's focus on maintaining dividend payments and cost savings targets through 2029, supporting its appeal as an income stock.
